Engineers Gate Manager LP Takes $1.87 Million Position in Haleon PLC Sponsored ADR $HLN

Engineers Gate Manager LP purchased a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,344 shares of the company’s stock, valued at approximately $1,869,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its stake in Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares during the period. Quotient Wealth Partners LLC boosted its stake in shares of Haleon by 7.9% during the 1st quarter. Quotient Wealth Partners LLC now owns 16,407 shares of the company’s stock valued at $164,000 after buying an additional 1,195 shares during the period. Clearstead Advisors LLC boosted its stake in shares of Haleon by 5.8% during the 4th quarter. Clearstead Advisors LLC now owns 25,847 shares of the company’s stock valued at $261,000 after buying an additional 1,406 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Haleon by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 63,726 shares of the company’s stock valued at $644,000 after acquiring an additional 1,431 shares in the last quarter. Finally, Personal CFO Solutions LLC grew its holdings in shares of Haleon by 11.5% during the 1st quarter. Personal CFO Solutions LLC now owns 15,673 shares of the company’s stock valued at $157,000 after acquiring an additional 1,620 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

HLN stock opened at $9.23 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $40.62 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 2.09 and a beta of 0.12. Haleon PLC Sponsored ADR has a 12 month low of $8.65 and a 12 month high of $11.28. The firm has a 50 day moving average of $9.84 and a two-hundred day moving average of $9.66.

Haleon Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be paid a $0.0642 dividend. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon’s payout ratio is presently 30.77%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Zacks Research raised Haleon from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK’s consumer healthcare business and became an independent company in 2022.